However, as high amounts of CXCL10 characterize vitiligo in an active phase [80], there is the possibility that the reported differences among immunotherapy-induced leukoderma and vitiligo could be less significant when only vitiligo patients in an active phase of the disease are included. This evidence concerns the gene CXCL10 and vitiligo.